Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Recro Pharma, Inc. Investors (REPH)

June 6, 2018

LOS ANGELES--(BUSINESS WIRE)--Jun 6, 2018--National law firm Glancy Prongay & Murray LLP (“GPM”) announces that a class action lawsuit has been filed on behalf of investors that purchased or otherwise acquired the securities of Recro Pharma, Inc. (“Recro Pharma” or the “Company”) (NASDAQ:  REPH ) between  July 31, 2017, and May 23, 2018, inclusive (the “Class Period”). Recro Pharma investors have until  July 30, 2018 to file a lead plaintiff motion.

To obtain information or actively participate in the class action, please visit the Recro Pharma page on our website at www.glancylaw.com/case/recro-pharma-inc.

Investors that suffered losses on their Recro Pharma investments are encouraged to contact Lesley Portnoy of GPM to discuss their legal rights in this class action at 310-201-9150 or by email to shareholders@glancylaw.com.

The complaint filed in this class action alleges that, Recro Pharma made false and misleading statements to the marketplace. The Company’s lead product, IV meloxicam, was unlikely to receive FDA approval due to lacking sufficient supporting clinical data to demonstrate significant clinical benefits. As a result, Recro Pharma’s public statements were materially false and misleading throughout the class period and did not accurately reflect the results of business operations and the financial health of the Company.

On May 24, 2018, Recro Pharma announced that it received a Complete Response Letter (“CRL”) from the U.S. Food and Drug Administration (“FDA”) regarding the Company’s New Drug Application (“NDA”) for IV meloxicam. In the CRL, the FDA informed the Company that the FDA was “unable to approve the application in its current form” because “data from ad hoc analyses and selective secondary endpoints suggest that the analgesic effect does not meet the expectations of the FDA” and “the CRL raised CMC related questions on extractable and leachable data provided in the NDA.”

On this news, Recro Pharma’s share price fell $6.79 per share, or 54.7%, to close at $5.63 per share on May 24, 2018, thereby injuring investors.

Follow us for updates on Twitter: twitter.com/GPM_LLP.

If you purchased shares of Recro Pharma during the Class Period you may move the Court no later than  July 30, 2018 to ask the Court to appoint you as lead plaintiff. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com:https://www.businesswire.com/news/home/20180606006410/en/

CONTACT: Glancy Prongay and Murray LLP, Los Angeles

Lesley Portnoy, 310-201-9150 or 888-773-9224





SOURCE: Glancy Prongay & Murray LLP

Copyright Business Wire 2018.

PUB: 06/06/2018 05:18 PM/DISC: 06/06/2018 05:47 PM


Update hourly